1. Home
  2. ENTA vs MMLP Comparison

ENTA vs MMLP Comparison

Compare ENTA & MMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • MMLP
  • Stock Information
  • Founded
  • ENTA 1995
  • MMLP 2002
  • Country
  • ENTA United States
  • MMLP United States
  • Employees
  • ENTA N/A
  • MMLP N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • MMLP Oil Refining/Marketing
  • Sector
  • ENTA Health Care
  • MMLP Energy
  • Exchange
  • ENTA Nasdaq
  • MMLP Nasdaq
  • Market Cap
  • ENTA 154.0M
  • MMLP 139.6M
  • IPO Year
  • ENTA 2013
  • MMLP 2002
  • Fundamental
  • Price
  • ENTA $5.27
  • MMLP $3.08
  • Analyst Decision
  • ENTA Buy
  • MMLP
  • Analyst Count
  • ENTA 4
  • MMLP 0
  • Target Price
  • ENTA $17.25
  • MMLP N/A
  • AVG Volume (30 Days)
  • ENTA 194.0K
  • MMLP 74.0K
  • Earning Date
  • ENTA 05-20-2025
  • MMLP 04-16-2025
  • Dividend Yield
  • ENTA N/A
  • MMLP 0.64%
  • EPS Growth
  • ENTA N/A
  • MMLP N/A
  • EPS
  • ENTA N/A
  • MMLP N/A
  • Revenue
  • ENTA $66,590,999.00
  • MMLP $719,335,000.00
  • Revenue This Year
  • ENTA N/A
  • MMLP $4.19
  • Revenue Next Year
  • ENTA N/A
  • MMLP N/A
  • P/E Ratio
  • ENTA N/A
  • MMLP N/A
  • Revenue Growth
  • ENTA N/A
  • MMLP N/A
  • 52 Week Low
  • ENTA $4.09
  • MMLP $2.56
  • 52 Week High
  • ENTA $17.24
  • MMLP $4.13
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 45.38
  • MMLP 53.19
  • Support Level
  • ENTA $4.96
  • MMLP $2.87
  • Resistance Level
  • ENTA $6.23
  • MMLP $3.18
  • Average True Range (ATR)
  • ENTA 0.33
  • MMLP 0.23
  • MACD
  • ENTA -0.01
  • MMLP 0.06
  • Stochastic Oscillator
  • ENTA 24.41
  • MMLP 81.82

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About MMLP Martin Midstream Partners L.P. Limited Partnership

Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.

Share on Social Networks: